Technical Analysis for ARWR - Arrowhead Research Corporation

Grade Last Price % Change Price Change
grade A 21.725 1.76% 0.38
ARWR closed up 12.72 percent on Tuesday, May 21, 2019, on 7.9 times normal volume. The bulls were able to push the stock to a new 52-week high.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical ARWR trend table...

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 1.76%
Expansion Breakout Bullish Swing Setup 1.76%
Pocket Pivot Bullish Swing Setup 1.76%
Volume Surge Other 1.76%
New 52 Week High Strength 1.76%
Above Upper BB Strength 1.76%
Gapped Up Strength 1.76%
NR7 Range Contraction 14.70%
NR7-2 Range Contraction 14.70%
NR7 Range Contraction 11.64%

Older signals for ARWR ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Arrowhead Research Corporation operates as a clinical stage therapeutics company. It has development programs in oncology, obesity, and chronic hepatitis B virus (HBV) infection. The company assembles a set of technologies, including Dynamic Polyconjugate platform, a RNA delivery system that addresses multiple organ systems and cell types, promotes multi-log gene knockdown in rodents and non-human primates, and induces endosomal escape; and RONDEL, a RNA delivery system for systemic siRNA delivery, and RNAi-mediated mRNA and protein knockdown in human melanoma patients. It also offers Homing Peptides platform, a library of short peptides for the development of peptide-drug conjugates and companion diagnostics. The company's principal product candidates include Adipotide, an anti-obesity peptide, which is in Phase I clinical trial for disrupting the blood supply that supports unhealthy fat by the targeted induction of apoptosis (cell death) in the vasculature of adipose tissue; ARC-520, an RNAi-based therapeutic to treat chronic HBV infection; and CALAA-01, an RNAi-based therapeutic that has completed a Phase IB clinical trial, which targets solid tumors. Its products also comprise CRLX-101 for NSC lung cancer; and Tubulin Inhibitor for oncology. The company, formerly known as InterActive Group, Inc., was founded in 2003 and is headquartered in Pasadena, California.
Biology Organ Systems Solid Tumors Infection Molecular Biology Obesity Genetics Gene Expression Hepatitis B RNA Molecular Genetics Apoptosis Chronic Hepatitis B Virus
Is ARWR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 22.74
52 Week Low 9.56
Average Volume 1,465,461
200-Day Moving Average 16.0709
50-Day Moving Average 18.778
20-Day Moving Average 18.7775
10-Day Moving Average 19.23
Average True Range 1.1357
ADX 13.59
+DI 37.0184
-DI 15.1623
Chandelier Exit (Long, 3 ATRs ) 19.3329
Chandelier Exit (Short, 3 ATRs ) 20.7071
Upper Bollinger Band 20.4695
Lower Bollinger Band 17.0855
Percent B (%b) 1.26
BandWidth 18.021568
MACD Line 0.3337
MACD Signal Line 0.1161
MACD Histogram 0.2176
Fundamentals Value
Market Cap 1.6 Billion
Num Shares 74.8 Million
EPS -0.64
Price-to-Earnings (P/E) Ratio -33.36
Price-to-Sales 11.15
Price-to-Book 2.81
PEG Ratio -1.10
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 24.73
Resistance 3 (R3) 24.81 23.78 24.16
Resistance 2 (R2) 23.78 22.92 23.73 23.97
Resistance 1 (R1) 22.56 22.39 23.17 22.48 23.79
Pivot Point 21.53 21.53 21.83 21.48 21.53
Support 1 (S1) 20.31 20.67 20.92 20.23 18.91
Support 2 (S2) 19.28 20.14 19.23 18.73
Support 3 (S3) 18.06 19.28 18.54
Support 4 (S4) 17.98